Alex C. Sapir Apppointed CEO of ReViral

HRS Scientific Sessions: Boston Scientific LBCT

During the Heart Rhythm Scientific Sessions this week, Boston Scientific announced positive LBCT data underscoring the safety and efficacy of multi-site pacing (MSP) over conventional cardiac resynchronization therapy (CRT), as well as poster presentations on real-world use of the WATCHMAN Left Atrial Appendage Closure (LAAC) device and next-generation WATCHMAN FLX LAAC device as alternatives to oral anticoagulation therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.

What are the Most Commonly Performed Surgeries?

Whether you are trying to learn more about a surgery you are planning to have or find out what the most common procedures are, this list is here for you. Read more.

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

Photo of Alex C. Sapir as Chief Executive OfficerAlex C. Sapir has been appointed CEO of ReViral.  Mr. Sapir was also elected to the Board of Directors, effective June 10, 2019. Mr. Sapir succeeds Dr. Eddy Littler, who will serve as Chief Operating Officer (COO).The news was announced today.

“Today, ReViral has a rich pipeline of wholly-owned RSV antiviral product candidates and strong research,” said Dr. Kenneth Powell, Chairman of the Board. “Alex’s proven leadership skills combined with his deep experience building biotech businesses make him ideally suited to take ReViral to the next level. On behalf of the Board of Directors, I’d also like to thank Eddy for his successful time at ReViral as CEO, where we now see the Company’s lead product, sisunatovir (RV521), poised to enter international, pediatric Phase II clinical trials this year. His leadership has been instrumental to ReViral’s evolution, and we look forward to benefiting from his continued input and guidance as COO.”

Alex C. Sapir brings to ReViral many years of combined strategic and commercial experience in the biotechnology industry. From 2016 through 2018, Alex was the President and CEO at Dova Pharmaceuticals (NASDAQ: DOVA). During Alex’s tenure, the company raised $160M through a successful Initial Public Offering (IPO) and subsequent follow-on offering. With those proceeds Dova Pharmaceuticals grew from a small, private, pre-commercial company to a 150-person, fully-integrated, publicly-traded biotech company with an approved and marketed product and a rich pipeline of ongoing clinical programs.

From January 2006 to May 2016, Alex C. Sapir served as Executive Vice President for United Therapeutics Corporation, a biotechnology company focused on pulmonary arterial hypertension and pediatric oncology. During his 10-year tenure at United Therapeutics, Alex was responsible for all commercial-related activity, seeing the company grow from a one product company generating $80M in revenues to a five-product company generating $1.6B annually. Mr. Sapir began his pharmaceutical career at GlaxoSmithKline, where he served in a variety of strategic and commercial roles in both the United States and Europe. He received his B.A. in Economics from Franklin and Marshall College and his MBA from Harvard Business School. He, along with Seth Hetherington, ReViral’s recently appointed Chief Medical Officer, will be based in North Carolina’s Research Triangle Park in the United States.

“I am honored to assume this role at such an important time in the Company’s evolution, and I look forward to working with the Company’s leadership, employees, and Board of Directors to develop novel RSV therapies that hold the potential to deliver life-changing outcomes for patients around the world,” said Mr. Sapir. “The morbidity and mortality associated with RSV remains high given the lack of available treatment options. With sisunatovir poised to enter Phase II trials, coupled with a strong portfolio of earlier-stage RSV candidates led by a world-renowned team of scientists with a track record of developing antiviral drugs, ReViral is well positioned to become a leader in the RSV market.”

“It has been a privilege to serve as the CEO of ReViral during its evolution into a clinical stage company, and I am delighted to welcome Alex on board,” said Dr. Littler. “Alex’s experience running public biotech companies will enable ReViral to realize its full potential as it continues to discover and develop transformative RSV therapies for patients in need.”

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.